Dr. Teresa Tarragó
Co-Founder & Chief Executive Officer (CEO)
Dr. Tarragó has a PhD in Molecular Biology from the University of Barcelona. She has solid expertise in drug discovery, gained during 15 years spent conducting several research lines on proteases and protease inhibitors at the Spanish National Research Council (CSIC) and IRB Barcelona. She has experience in managing internationally-funded research projects, as well as directing joint undertakings with biotech companies. She has published over 40 papers and two books, and she holds four patents. In addition to her scientific qualifications, she holds an Executive MBA (ESADE) and has participated in entrepreneurship programmes, including “Ignite” at Cambridge Judge Business School and “BioEmprendedor XXI” (Barcelona).
Dr. Roger Prades
Chief Scientific Officer (CSO)
Dr. Prades has a PhD in Chemistry from the University of Barcelona and an Executive Master’s Degree in Innovation from the Industrial Organization School (EOI). He has expertise in peptide synthesis and ADME drug profiling, particularly in determining the capacity of compounds to cross the Blood-Brain Barrier (BBB) in several in vitro models. During his pre-doctoral training period at IRB Barcelona, he spent a 6-month internship at Department of Diagnostic Radiology at the Yale School of Medicine (USA). He has published nine papers in international peer-reviewed journals and holds three patents.
Dr. Laura Mendieta
Chief Operations Officer (COO)
Dr. Mendieta has a PhD in Biotechnology and a Postgraduate Degree in Innovation Management from the University of Barcelona, and an Executive Master’s Degree in Innovation from the Industrial Organization School (EOI). She was a pre-doctoral researcher at IRB Barcelona, where she focused on the discovery of protease inhibitors as therapeutic agents. She has participated in internships at the Harvard Medical School (USA), the Glasgow Biomedical Research Centre (UK), and the Universidade Federal de Santa Maria (Brazil).
Dr. Jesus Seco
Head of Computational Chemistry
Dr. Seco holds a PhD in Pharmacy from the University of Barcelona, where he focused on rational computer-based drug design. After completing his doctoral period, he moved to the University of Oklahoma (USA), and then gained an Executive Master’s Degree in Innovation from Industrial Organization School (EOI). He is proficient in the most advanced computer approaches currently used in drug design, such as biomolecular simulations, docking techniques, chemo-informatics and bio-informatics, as well as systems biology. He has participated in several academia-industrial partnerships with pharmaceutical companies, including Uriach, Sanofi, Noscira and Oryzon.
Chief Financial Officer (CFO)
Xavier has a BBA and an MBA from ESADE (Barcelona) and is UK qualified (CIMA Adv Dip MA). Among other senior finance roles, he managed FP&A EMEA for a division of Applied Biosystems between 2007 and 2013. After this, he went on to cofound Metrix Partners where he advises startups in strategy, corporate and operational finance. Xavier is also a partner of Spire Bioventures, a mentor network in Silicon Valley and Barcelona that advises biotech and medical devices companies across all functional areas.